Effect of angiotensin converting enzyme inhibitor and angiotensin II receptor blocker on the patients with sepsis
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Inhibitors of the renin-angiotensin system, angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs), reportedly have anti-inflammatory effects. This study assessed the association of prior use of ACE inhibitors and ARBs with sepsis-related clinical outcomes. Methods: A population-based observational study was conducted using the Health Insurance Review and Assessment Service claims data. Among the adult patients hospitalized with new onset of sepsis in 2012, patients who took ARBs or ACE inhibitors at least 30 days prior to hospitalization were analyzed. Generalized linear models and logistic regression were used to examine the relation between the prior use of medication and clinical outcomes, such as in-hospital mortality, mechanical ventilation, and length of stay. Results: Of a total of 27,628 patients who were hospitalized for sepsis, the ACE inhibitor, ARB, and non-user groups included 1,214 (4.4%), 3,951 (14.4%), and 22,463 (82.1%) patients, respectively. As the patients in the ACE inhibitor and ARB groups had several comorbid conditions, higher rates of intensive care unit admission, hemodialysis, and mechanical ventilation were observed. However, after covariate adjustment, the use of ACE inhibitor (odds ratio [OR], 0.752; 95% confidence interval [CI], 0.661 to 0.855) or ARB (OR, 0.575; 95% CI, 0.532 to 0.621) was significantly associated with a lower rate of in-hospital mortality. Conclusions: Pre-hospitalization use of ACE inhibitors or ARBs for sepsis was an independent factor for a lower rate of in-hospital mortality.
Abstract
Background/Aims: Inhibitors of the renin-angiotensin system, angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs), reportedly have anti-inflammatory effects. This study assessed the association of prior use of ACE inhibitors and ARBs with sepsis-related clinical outcomes. Methods: A population-based observational study was conducted using the Health Insurance Review and Assessment Service claims data. Among the adult patients hospitalized with new onset of sepsis in 2012, patients who took ARBs or ACE inhibitors at least 30 days prior to hospitalization were analyzed. Generalized linear models and logistic regression were used to examine the relation between the prior use of medication and clinical outcomes, such as in-hospital mortality, mechanical ventilation, and length of stay. Results: Of a total of 27,628 patients who were hospitalized for sepsis, the ACE inhibitor, ARB, and non-user groups included 1,214 (4.4%), 3,951 (14.4%), and 22,463 (82.1%) patients, respectively. As the patients in the ACE inhibitor and ARB groups had several comorbid conditions, higher rates of intensive care unit admission, hemodialysis, and mechanical ventilation were observed. However, after covariate adjustment, the use of ACE inhibitor (odds ratio [OR], 0.752; 95% confidence interval [CI], 0.661 to 0.855) or ARB (OR, 0.575; 95% CI, 0.532 to 0.621) was significantly associated with a lower rate of in-hospital mortality. Conclusions: Pre-hospitalization use of ACE inhibitors or ARBs for sepsis was an independent factor for a lower rate of in-hospital mortality.
참고문헌 (43)
- Atlas SA, "The renin-angiotensin aldosterone system : pathophysiological role and pharmacologic inhibition", J Manag Care Pharm, 13, pp.9~20 (2007)
- Doerschug KC, "Renin-angiotensin system activation correlates with microvascular dysfunction in a prospective cohort study of clinical sepsis", Crit Care, 14, pp.R24~ (2010)
- Zhang W, "Severe sepsis : low expression of the renin-angiotensin system is associated with poor prognosis", Exp Ther Med, 7, pp.1342~1348 (2014)
- Wan L, "Angiotensin II in experimental hyperdynamic sepsis", Crit Care, 13, pp.R190~ (2009)
- Correa TD, "Angiotensin II in septic shock : effects on tissue perfusion, organ function, and mitochondrial respiration in a porcine model of fecal peritonitis", Crit Care Med, 42, pp.e550~e559 (2014)
- Khanna A, "Angiotensin II for the treatment of vasodilatory shock", N Engl J Med, 377, pp.419~430 (2017)
- Imai Y, "Angiotensin-converting enzyme 2 protects from severe acute lung failure", Nature, 436, pp.112~116 (2005)
- du Cheyron D, "Hyperreninemic hypoaldosteronism : a possible etiological factor of septic shock-induced acute renal failure", Intensive Care Med, 29, pp.1703~1709 (2003)
- Lund DD, "Role of angiotensin II in endothelial dysfunction induced by lipopolysaccharide in mice", Am J Physiol Heart Circ Physiol, 293, pp.H3726~H3731 (2007)
- Laesser M, "The angiotensin II receptor blocker candesartan improves survival and mesenteric perfusion in an acute porcine endotoxin model", Acta Anaesthesiol Scand, 48, pp.198~204 (2004)
- Mortensen EM, "Impact of previous statin and angiotensin II receptor blocker use on mortality in patients hospitalized with sepsis", Pharmacotherapy, 27, pp.1619~1626 (2007)
- Ohtsubo T, "Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers in hypertensive patients with myocardial infarction or heart failure : a systematic review and meta-analysis", Hypertens Res, 42, pp.641~649 (2019)
- Tai C, "Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular events in patients with heart failure : a meta-analysis of randomized controlled trials", BMC Cardiovasc Disord, 17, pp.257~ (2017)
- Wang K, "Effects of Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality and renal outcomes in patients with diabetes and albuminuria : a systematic review and meta-analysis", Kidney Blood Press Res, 43, pp.768~779 (2018)
- Mortensen E, "Association of outpatient statin, ARB, and ACE inhibitor use on clinical outcomes for elderly subjects hospitalized with severe sepsis", Eur Respir J, 42(Suppl 57), pp.4840~ (2013)
- Suberviola B, "Association between exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers prior to septic shock and acute kidney injury", Med Intensiva, 41, pp.21~27 (2017)
- Mawri S, "Pre-hospital use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers is associated with improved outcomes in patients hospitalized with septic shock", Integr Clin Cardiol, 6, pp.006~ (2017)
- DeMott JM, "Effects of chronic antihypertensives on vasopressor dosing in septic shock", Ann Pharmacother, 52, pp.40~47 (2018)
- von Elm E, "The Strengthening the Reporting of Observational Studies in Epidemiology(STROBE)statement : guidelines for reporting observational studies", Lancet, 370, pp.1453~1457 (2007)
- 김지애, "Towards Actualizing the Value Potential of Korea Health Insurance Review and Assessment (HIRA) Data as a Resource for Health Research: Strengths, Limitations, Applications, and Strategies for Optimal Use of HIRA Data", Journal of Korean Medical Science, 32(5), pp.718~728 (2017), 대한의학회
- Levy MM, "SCCM", ESICM, ATS, pp.SIS International Sepsis Definitions Conference, Crit Care Med[DOI]
- Singer M, "The third International Consensus Definitions for Sepsis and Septic Shock(Sepsis-3)", JAMA, 315, pp.801~810 (2016)
- Li Y, "Angiotensin-converting enzyme inhibition attenuates lipopolysaccharide-induced lung injury by regulating the balance between angiotensin-converting enzyme and angiotensin-converting enzyme 2 and inhibiting mitogen-activated protein kinase activation", Shock, 43, pp.395~404 (2015)
- Erwin BL, "Evaluation of vasopressin for septic shock in patients on chronic renin-angiotensin-aldosterone system inhibitors", Crit Care Med, 45, pp.e1226~e1232 (2017)
- Correa TD, "Angiotensin II in septic shock", Crit Care, 19, pp.98~ (2015)
- Benigni A, "Angiotensin II revisited : new roles in inflammation, immunology and aging", EMBO Mol Med, 2, pp.247~257 (2010)
- Salvador GL, "Angiotensin-converting enzyme inhibitors reduce mortality compared to angiotensin receptor blockers : systematic review and meta-analysis", Eur J Prev Cardiol, 24, pp.1914~1924 (2017)
- Caldeira D, "Risk of pneumonia associated with use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers:systematic review and meta-analysis", BMJ, 345, pp.e4260~ (2012)
- Gullestad L, "Effect of high-versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure", J Am Coll Cardiol, 34, pp.2061~2067 (1999)
- Peeters AC, "The effect of renin-angiotensin system inhibitors on pro-and anti-inflammatory cytokine production", Immunology, 94, pp.376~379 (1998)
- Stenvinkel P, "Do ACE-inhibitors suppress tumour necrosis factor-alpha production in advanced chronic renal failure?", J Intern Med, 246, pp.503~507 (1999)
- Hagiwara S, "Effects of an angiotensin-converting enzyme inhibitor on the inflammatory response in in vivo and in vitro models", Crit Care Med, 37, pp.626~633 (2009)
- Manabe S, "Effects of angiotensin II receptor blockade with valsartan on pro-inflammatory cytokines in patients with essential hypertension", J Cardiovasc Pharmacol, 46, pp.735~739 (2005)
- Fliser D, "Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation", Circulation, 110, pp.1103~1107 (2004)
- Marchesi C, "Role of the renin-angiotensin system in vascular inflammation", Trends Pharmacol Sci, 29, pp.367~374 (2008)
- Guo J, "Effects of angiotensin II type 1 receptor antagonist on rats with septic shock", Int J Clin Exp Med, 8, pp.7867~7871 (2015)
- Hagiwara S, "Antagonist of the type-1 ANG II receptor prevents against LPS-induced septic shock in rats", Intensive Care Med, 35, pp.1471~1478 (2009)
- Dial S, "Antihypertensive agents acting on the renin-angiotensin system and the risk of sepsis", Br J Clin Pharmacol, 78, pp.1151~1158 (2014)
- Kim J, "Effect of antihypertensive medications on sepsis-related outcomes : a population-based cohort study", Crit Care Med, 47, pp.e386~e393 (2019)
- Lim HJ, "Renin-angiotensin-aldosterone system blockade in critically ill patients is associated with increased risk for acute kidney injury", Tohoku J Exp Med, 238, pp.17~23 (2016)
- Harty J, "Prevention and management of acute kidney injury", Ulster Med J, 83, pp.149~157 (2014)
- Tumlin JA, "Outcomes in patients with vasodilatory shock and renal replacement therapy treated with intravenous angiotensin II", Crit Care Med, 46, pp.949~957 (2018)
- Hsieh MS, "Preadmission antihypertensive drug use and sepsis outcome : impact of angiotensin-converting enzyme inhibitors(ACEIs)and angiotensin receptor blockers(ARBs)", Shock, 53, pp.407~415 (2020)